You are here

JPMHC 2023

Will 2023 Usher in a New Era for Medtech M&A?

Will 2023 Usher in a New Era for Medtech M&A?

Medical Devices and Diagnostics Industry

Flag link:

At buzzy health care business conference, investors fear the bubble will burst

At buzzy health care business conference, investors fear the bubble will burst

NPR

Flag link:

3 biotech executives on the year ahead: deals, drug pricing and the down market

3 biotech executives on the year ahead: deals, drug pricing and the down market

BioPharma Dive

Ovid Therapeutics

Flag link:

How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon

How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon

Fierce Biotech

Agios Pharmaceuticals

Cerevel Therapeutics

Flag link:

A trio of biotechs consolidate as M&A fails to materialize at JPM

A trio of biotechs consolidate as M&A fails to materialize at JPM

Fierce Biotech

Leap Therapeutics

Flame Biosciences

Flag link:

JPM2023: Breakthroughs await, but so do roadblocks

JPM2023: Breakthroughs await, but so do roadblocks

Pharmaphorum

Inflation Reduction Act

clinical trials

Flag link:

JPM23: Is GSK's 15-day accelerated approval withdrawal the new normal? Hear FDA Commissioner Robert Califf's response

JPM23: Is GSK's 15-day accelerated approval withdrawal the new normal? Hear FDA Commissioner Robert Califf's response

Fierce Pharma

Flag link:

Did Storms Steal JPM's Thunder?

Did Storms Steal JPM's Thunder?

Medical Devices and Diagnostics Industry

Flag link:

JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit

JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit

Fierce Biotech

Dicerna Pharmaceuticals

Flag link:

JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says

JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says

Fierce Pharma

Flag link:

JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

BioPharma Dive

Bristol Myers Squibb

Flag link:

JPM23 squawk box: What’s changing – and what isn’t – at big healthcare companies

JPM23 squawk box: What’s changing – and what isn’t – at big healthcare companies

Medical Marketing and Media

Flag link:

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

Looking past Humira, AbbVie boosts sales forecasts for successor drugs

BioPharma Dive

Richard Gonzalez

Flag link:

JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas

BioPharma Dive

venture capital

Flag link:

JPM23, Day 3: Takeda relishing in-person meetups

JPM23, Day 3: Takeda relishing in-person meetups

Fierce Biotech

Flag link:

JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says

JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says

Fierce Pharma

Flag link:

JPM Day 2: Highlights

JPM Day 2: Highlights

BioSpace

Relay Therapeutics

SAGE Therapeutics

Karuna Therapeutics

Flag link:

Merck Highlights Growth Strategy at J.P. Morgan

Merck Highlights Growth Strategy at J.P. Morgan

BioSpace

Flag link:

Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM

Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM

BioSpace

Flag link:

JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

Fierce Biotech

Karuna Therapeutics

Flag link:

Pages